Curium Pharma in the news

Curium Pharma is in talks to acquire radiopharmaceutical company Lantheus Holdings for about $7 billion.

Curium is reportedly in advanced talks to acquire radiopharmaceutical rival Lantheus for $7 billion, while also reintroducing a cardiac imaging radiotracer to the U.S. market.

Curium is acquiring radiopharma rival Lantheus for up to $8 billion to create a comprehensive nuclear medicine company.

Curium is set to acquire Lantheus for up to $8.0 billion, combining their radiopharmaceutical and radiodiagnostic capabilities to serve patients globally.

Curium is acquiring radiopharma rival Lantheus in an $8 billion deal to create a combined company with $2.1 billion in annual revenues, specializing in diagnostic and therapeutic radiopharmaceuticals.

Curium is acquiring Lantheus Holdings for a deal valued at up to $8 billion, offering shareholders a premium with potential for additional payouts based on future sales.

Curium is investing over €32 million to establish a new prostate cancer therapy production line in Saclay, France.

Curium Pharma secured new debt facilities and a capital injection from its lead sponsor CVC.

Radiopharmaceutical firm Lantheus is considering a $7 billion sale to its competitor Curium Pharma amid recent regulatory delays and legal challenges.

Curium Pharma is reportedly in talks to acquire radiopharmaceutical specialist Lantheus for approximately $7 billion.

Curium Pharma has made a $7 billion offer to acquire radiopharmaceutical peer Lantheus Holdings.

Lantheus Holdings is considering a $7 billion acquisition offer from Curium Pharma.

Radiopharmaceutical company Lantheus is considering a $7 billion takeover offer from its competitor Curium Pharma.

Lantheus is evaluating a potential $7 billion takeover bid from Curium in the radiopharmaceutical sector.

Sabine Brookman-May has joined Curium Pharma as VP Global Head of Clinical Development to lead radiopharmaceutical portfolio strategy and prostate cancer diagnostics.

Curium Pharma has secured a $7 billion financing deal to accelerate its shift from medical diagnostics to advanced cancer therapies.

A global radiopharmaceutical leader is relocating its headquarters to a 6,982-square-foot Class-A office space in Boston's Seaport district.

CapVest Partners is moving its $7 billion nuclear medicine company Curium Pharma into a new continuation fund led by TPG, ICG, and CVC.

Curium reaches a record $7 billion valuation through a major ownership restructuring to fuel its expansion in nuclear medicine and cancer therapy.

Renaud Dehareng, CEO of nuclear medicine leader Curium Pharma, discusses his goal to treat 80% of cancers using targeted radioactive therapy.